Which lipid-lowering medication is first-line for ASCVD risk reduction and how does it function?

• A. Fibrates; increase HDL only.
• B. Niacin; increase LDL.
• C. Statins; inhibit HMG-CoA reductase to reduce cholesterol synthesis and LDL levels.
• D. Bile acid sequestrants; increase LDL.

Answer: (C)

Statins are first-line for ASCVD risk reduction because they consistently lower major cardiovascular events across diverse populations, making them the most proven and widely used option for reducing risk beyond just lowering cholesterol levels.

They work by inhibiting the enzyme HMG-CoA reductase, which is the rate-limiting step in hepatic cholesterol synthesis. With less cholesterol being made in the liver, the cells sense lower cholesterol and upregulate LDL receptors on their surface. Those receptors pull more LDL cholesterol from the bloodstream, leading to a significant drop in circulating LDL levels. This reduction in LDL translates into slower atherosclerotic progression and fewer heart attacks and strokes over time.

Other therapies can lower LDL or improve lipid profiles in different ways, but they do not offer the same consistently robust evidence for reducing ASCVD events as statins, and they are typically reserved for specific scenarios (such as very high triglycerides, statin intolerance, or particular patient needs).